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Defined transcription factors can induce epigenetic reprogramming of adult mammalian cells into 
induced pluripotent stem cells. Although DNA factors are integrated during some reprogramming 
methods, it is unknown whether the genome remains unchanged at the single nucleotide level. 
Here we show that 22 human induced pluripotent stem (hiPS) cell lines reprogrammed using five 
different methods each contained an average of five protein-coding point mutations in the regions 
sampled (an estimated six protein coding point mutations per exome). The majority of these 
mutations were non-synonymous, nonsense, or splice variants, and were enriched in genes 
mutated or having causative effects in cancers. At least half of these reprogramming-associated 
mutations pre-existed in fibroblast progenitors at low frequencies, while the rest were newly 
occurring during or after reprogramming. Thus, hiPS cells acquire genetic modifications in 
addition to epigenetic modifications. Extensive genetic screening should become a standard 
procedure to ensure hiPS safety before clinical use.
Introduction
hiPS cells have the potential to revolutionize personalized medicine by allowing 
immunocompatible stem cell therapies to be developed1,2. However, questions remain 
about hiPS safety. For clinical use, hiPS lines must be reprogrammed from cultured adult 
cells, and could carry a mutational load due to normal in vivo somatic mutation. 
Furthermore, many hiPS reprogramming methods utilize oncogenes that may increase the 
mutation rate. Additionally, some hiPS lines have been observed to contain large-scale 
genomic rearrangements and abnormal karyotypes after reprogramming3. Recent studies 
also revealed that tumor suppressor genes, including those involved in DNA damage 
response, have an inhibitory effect on nuclear reprogramming4-9. These findings suggest 
that the process of reprogramming could lead to an elevated mutational load in hiPS cells.
To probe this issue, we sequenced the majority of the protein-coding exons (exomes) of 
twenty-two hiPS lines and the nine matched fibroblast lines from which they originated 
(Table 1). These lines were reprogrammed in seven laboratories using three integrating 
methods (four-factor retroviral, four-factor lentiviral, and three-factor retroviral) and two 
non-integrating methods (episomal vector and mRNA delivery into fibroblasts). All hiPS 
lines were extensively characterized for pluripotency and had normal karyotypes prior to 
DNA extraction (Supplementary Methods). Protein coding regions in the genome were 
captured and sequenced from the genomic DNA of hiPS lines and their matched progenitor 
fibroblast lines using either padlock probes10,11 or in-solution DNA or RNA baits12,13. 
We searched for single base changes, small insertions/deletions, and alternative splicing 
variants, and identified 12,000 - 18,000 known and novel variants for each cell line that had 
sufficient coverage and consensus quality (Table 1).
hiPS Cell Lines contain a High Level of Mutational Load
We identified sites that showed the gain of a new allele in each hiPS line compared with 
their corresponding matched progenitor fibroblast genome. A total of 124 mutations were 
validated with capillary sequencing (Figure 1, Table 2, Supplementary Figure S1), which 
revealed that each mutation was fixed in heterozygous condition in the hiPS lines. No small 
insertions/deletions were detected. For three hiPS lines (CV-hiPS-B, CV-hiPS-F, PGP1-
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iPS), the donor’s complete genome sequence obtained from whole blood is publicly 
available14,15; we used this information to further confirm that all 27 mutations in these 
lines were bona fide somatic mutations. Because 84% of the expected exomic variants16 
were captured at high depth and quality, the predicted load is approximately 6 coding 
mutations per hiPS genome (see Table 1 for details). The majority of mutations were 
missense (83/124), nonsense (5/124), or splice variants (4/124). Fifty-three missense 
mutations were predicted to alter protein function17 (Supplementary Table S1). Fifty 
mutated genes were previously found to be mutated in some cancers18,19. For example, 
ATM is a well-characterized tumor suppressor gene found mutated in one hiPS line, while 
NTRK1 and NTRK3 (tyrosine kinase receptors) can cause cancers when mutated20 and 
contained damaging mutations in three hiPS lines (CV-hiPS-F, iPS29e, FiPS4F-shpRB4.5) 
reprogrammed in three labs from different donors. Two NEK kinase genes, a family related 
to cell division, were mutated in two independent hiPS lines. In addition to cancer-related 
genes, fourteen of the twenty-two lines contain mutations in genes with known roles in 
human Mendelian disorders21. Three pairs of hiPS lines (iPS17a and iPS17b, dH1F-iPS8 
and dH1F-iPS9, CF-RiPS1.4 and CF-RiPS 1.9) shared three, two, and one mutation 
respectively; these most likely arose in shared common progenitor cells prior to 
reprogramming. However, most hiPS lines derived from the same fibroblast line did not 
share common mutations (Table 2 and Supplementary Table S1).
These data raise the possibility that a significant number of mutations are occurring during 
or shortly after reprogramming and then become fixed during colony picking and expansion. 
An alternative hypothesis is that the mutations we found are simply the result of age-accrued 
biopsy heterogeneity or in vitro fibroblast cell culture. The skin biopsies were collected from 
donors at ages varying from newborn to 82 years old; biopsy heterogeneity therefore does 
not appear to play a primary role, as the mutational load is not correlated (R2 = 0.046) with 
donor age (Supplementary Figure S2). We attempted to grow clonal fibroblasts in order to 
obtain a control for single-cell mutational load, but a direct assessment was not possible due 
to technical difficulties in mimicking the exact culture conditions (Supplementary Methods). 
Assuming the skin biopsy is mutation-free, we can use previously published values for the 
typical mutation rate in culture to obtain an expectation of ten times fewer mutations per 
genome than we observed (p< 1.27 × 10−53; Supplementary Methods), indicating that hiPS 
mutational load is high compared to normal culture mutational load. We define the term 
“reprogramming-associated mutations” to describe mutations observed after 
reprogramming. Reprogramming-associated mutations could be pre-existing at low 
frequencies in the fibroblast population, occurring during the reprogramming process, or 
occurring after reprogramming. All reprogramming-associated mutations have become fixed 
in the hiPS line population.
Reprogramming-Associated Mutations arise through Multiple Mechanisms
To test whether some observed mutations were present in the starting fibroblasts at low 
frequency prior to reprogramming, we developed a new digital quantification assay (DigiQ) 
to quantify the frequencies of 32 mutations in six fibroblast lines using ultra-deep 
sequencing (Supplementary Figure S3-4). We amplified each mutated region from the 
genomic DNA of 100,000 cells with a high-fidelity DNA polymerase and sequenced the 
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pooled amplicons with an Illumina Genome Analyzer at an average coverage of 106. 
Although the raw sequencing error is roughly 0.1-1% with the Illumina sequencing 
platform, detection of rare mutations at a lower frequency is possible with proper quality 
filtering and careful selection of controls22. For each fibroblast line, we included the 
mutation-carrying hiPS DNA as the positive control and another “mutation-free” DNA 
sample as the negative control for sequencing errors (Supplementary Methods). Comparison 
of the allelic counts at the mutation positions between the fibroblast lines and the negative 
controls allowed us to distinguish rare mutations from sequencing errors, and estimate the 
detection limit of the assay. Seventeen of the 32 mutations were found in fibroblasts in a 
range of 0.3-1000 in ten thousand while 15 mutations were not detectable (Supplementary 
Table S2-3). In each fibroblast line with more than one detectable rare mutation, the 
frequency of each mutation was very similar, which suggests that a small sub-population of 
each fibroblast line appeared to contain all pre-existing hiPS mutations, while the rest of the 
cells lacked any of them.
We extended this analysis by asking whether all of the hiPS mutations could have pre-
existed in the fibroblast populations. For the 15 mutations not detected with the DigiQ assay, 
the detection limits can be estimated (Supplementary Methods). The sequencing quality was 
sufficiently high at 7 of the 15 sites such that rare mutations at frequencies of 0.6-5 in 
100,000 should be detectable with our assay (Supplementary Table S3). Since 
30,000-100,000 fibroblast cells were used in the reprogramming experiments, we can rule 
out the presence of two mutated genes (NTRK3 and PLOR1C) in even one cell of the 
starting fibroblast population, while five others were present in no more than 1-2 cells.
As another test of the hypothesis that all of the mutations pre-existed in fibroblasts prior to 
reprogramming, we examined the exomes of two hiPS lines derived from a fibroblast line 
dH1cf16, which was itself clonally derived from the dH1F fibroblast line and passaged the 
minimum amount to generate enough cells for reprogramming. The two hiPS lines derived 
from the non-clonal dH1F fibroblast line contained 8 and 3 new mutations not found in the 
fibroblasts respectively; we observed a very similar independent mutational load in the 
clonal lines (6 new mutations in the hiPS line dH1cf16-iPS1 and 2 new mutations in the 
hiPS line dH1cf16-iPS4). Together, these experiments establish that while some of the 
reprogramming-associated mutations were likely to pre-exist in the starting fibroblast 
cultures, the others occurred during reprogramming and subsequent culture. Specific 
distributions tend to vary across hiPS lines (Supplementary Table S3).
Mutations occurring during reprogramming could be due in part to a significantly elevated 
mutation rate during reprogramming. It is also possible that selection could play an 
important role. We tested the possibility that an elevated mutation rate might occur because 
the reprogramming process might be inducing transient repression of p53, RB1, and other 
tumor suppressor genes, which are known to inhibit reprogramming and are required for 
normal DNA damage responses. SV40 Large-T antigen, which inactivates tumor suppressor 
and DNA damage response genes (including p53 and p105/RB1)23, was expressed during 
reprogramming of three analyzed hiPS lines (DF6-9-9, DF19-11, and iPS4.7).24. Another 
hiPS line (FiPS4F-shpRB4.5) was generated while directly knocking down RB1 
(Supplementary Figure S5). However, the observed mutational load was very similar in 
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these lines compared to the others, indicating that reprogramming-associated mutations 
cannot be explained by an elevated mutation rate caused by p53 or RB1 repression.
We also probed if additional mutations could become fixed during extended passaging by 
extending our analysis of one hiPS line. While most of our hiPS lines were sequenced at 
fairly low passage number (less than 20), to directly measure the effect of post-
reprogramming culture we also sequenced one hiPS line (FiPS4F2) at two passages (p9 and 
p40). We discovered that all seven mutations identified in the passage 9 line remained fixed 
in the passage 40 line, but that four additional mutations were found to be fixed in the 
passage 40 cell line.
To test the possibility that selection is operating during hiPS generation, we performed an 
enrichment analysis to determine if reprogramming-associated mutated genes were more 
likely to be observed in cancer cells than random somatic mutation. We used the COSMIC 
database as a source of genes commonly mutated in cancer. We discovered that the 
reprogramming-associated mutated genes were significantly enriched for genes found 
mutated in cancer (p=0.0019, Supplementary Materials), which implies some mutations 
were selected during reprogramming.
As an alternative test of the selection hypothesis, we asked whether mutations associated 
with reprogramming could be functional based on the nonsynonymous:synonymous (NS:S) 
ratio. Traditionally, the analysis of the NS:S ratio is applied to germline mutations evolved 
over a long period of evolutionary time, which is thus not directly applicable to somatic 
mutations. However, functional mutations are known to be positively selected in cancers, 
allowing us to make a direct comparison to mutation characteristics found in cancer 
genomes. Strikingly the NS:S ratio is very similar between mutations identified in three 
recent cancer genome sequencing projects25,26,27 and the reprogramming-associated 
mutations we found (2.4:1 and 2.6:1, respectively), indicating that a similar degree of 
selection pressure may be present.
We also checked if reprogramming-associated mutations could be providing a common 
functional advantage using a pathway enrichment analysis through Gene Ontology terms28. 
No statistically significant similarity was identified, indicating that mutated genes have 
varied cellular functions. Again, identical results were found when performing the same 
analysis on mutations identified during the genome sequencing of melanoma, breast cancer, 
and lung cancer samples25,26,27. This lack of enrichment in cancer genomes is generally 
thought to be due to the presence of many passenger mutations in cancer cells, which could 
also be true for reprogramming-associated mutations. Nonetheless, these analyses suggest 
that selection of potentially functional mutations could play a role in amplifying rare 
mutation-carrying cells and, when coupled with the single-cell bottleneck in hiPS colony 
picking, could contribute to the fixation of initially low-frequency mutations throughout the 
entire hiPS cell population.
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Discussion
Taken together, our results clearly demonstrate that pre-existing and new mutations during 
and after reprogramming all contribute to the high mutational load we discovered in hiPS 
lines. Although we cannot completely rule out the possibility that reprogramming itself is 
“mutagenic”, our data argue that selection during hiPS reprogramming, colony-picking, and 
subsequent culture may be contributing factors. A corollary is that, if reprogramming 
efficiency is improved to a level such that no colony-picking and clonal expansion is 
necessary, the resulting hiPS cells could potentially be free of mutations.
Despite the power of our experimental approach to accurately identify and characterize 
reprogramming-associated mutations, their functional significance remains to be shown. 
This issue parallels a general problem facing the genomics community: high-throughput 
sequencing technologies have allowed data generation rates to greatly outpace functional 
interpretation. Additionally, when considering the biological significance of 
reprogramming-associated mutations, there are two separate functional aspects to consider: 
whether some of these mutations contributed functionally to the reprogramming of cell fate, 
and whether some of these mutations could increase disease risk when hiPS-derived cells/
tissues are used in the clinic. These two aspects are not necessarily connected. Although the 
functional effects of the 124 mutations remained to be characterized experimentally, it is 
nonetheless striking that the observed reprogramming-associated mutational load shares 
many similarities with that observed in cancer. Furthermore, the observation of mutated 
genes involved in human Mendelian disorders suggests that the risk for diseases other than 
cancer needs to be evaluated for hiPS-based therapeutic methods. Future long-term studies 
must focus on functional characterization of reprogramming-associated mutations in order to 
further aid the creation of clinical safety standards.
Because safe hiPS cells are critical for clinical application, just as previous findings of large-
scale genome rearrangements in hiPS lines led to the introduction of karyotyping as a 
standard post-reprogramming protocol, routine genetic screening of hiPS lines to ensure that 
no obviously deleterious point mutations are present must become a standard procedure. 
Complete exome or genome sequencing of hiPS lines might be an efficient way to screen 
out hiPS lines that have a high mutational load or that have mutations in genes implicated in 
development, disease, or tumorigenesis. Further rigorous work on mutation rates and 
distributions during in vitro culture and reprogramming of hiPS cells, and perhaps human 
embryonic stem cells, will be essential to help establish clinical safety standards for genomic 
integrity.
Methods Summary
CV-hiPS-F and CV-hiPS-B were reprogrammed from CV Fibroblasts using 4-factor 
retroviral vectors. PGP1-iPS cells were reprogrammed by Cellular Dynamics using the same 
four factors in a lentiviral vector from PGP1F fibroblasts29. dH1F-iPS8, dH1F-iPS9, 
dH1cF16-iPS1, dH1cF16-iPS4, dH1cF16, and dH1F cells were obtained from previous 
cultures30 reprogrammed with retroviral vectors containing the same factors31. DF-6-9-9, 
DF-19-11, iPS4.7, and FS cells were obtained from previously existing cultures; the 
Gore et al. Page 6
Nature. Author manuscript; available in PMC 2011 September 03.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
reprogramming process and characterization of lines has been described previously24. 
iPS11a, iPS11b, iPS17a, iPS17b, iPS29A, iPS29e, Hib11, Hib17, and Hib29 cells were 
obtained from previous cultures reprogrammed using retroviral vectors encoding three or 
four factors32. FiPS3F1 and FiPS4F7 were reprogrammed from HFFxF fibroblasts using 
similar protocols33-35. FiPS4F2 and FiPS4F-shpRB4.5 were reprogrammed using the same 
4-factor protocol from IMR90 fibroblasts. The mRNA-derived lines (CF-RiPS1.4, CF-
RiPS1.9, and CF Fibroblasts) were obtained from previous cultures36. All hiPS lines were 
extensively characterized for pluripotency. Fourteen lines were tested for teratoma formation 
and shown to express all embryonic germ layers in vivo. DNA was extracted from each cell 
type using Qiagen’s DNeasy kit.
Exome capture was performed with either a library of padlock probes, commercial 
hybridization capture DNA baits (NimbleGen SeqCap EZ), or RNA baits (Agilent 
SureSelect), and the resulting libraries were sequenced on an Illumina GA IIx sequencer. 
Putative mutations were rejected if they were known polymorphisms or contained any minor 
allele presence in the fibroblast. All candidate mutations were confirmed using capillary 
Sanger sequencing.
For digital quantification, mutations were PCR-amplified and sequenced using an Illumina 
GA IIx. These libraries were sequenced to obtain on average one million independent base 
calls for each location. A binomial test was then used to determine if the observed minor 
allele frequency could be separated from error and estimate the frequency of each mutation.
Detailed methods are available in the Supplementary Materials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. hiPS acquired protein-coding somatic mutations
Somatic mutations in the gene NTRK3 were found in two independent hiPS lines but were 
not present in their fibroblast progenitors. Detailed information for all mutations is in the 
Supplementary Materials.
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Table 2
List of genes found to be mutated in coding regions in hiPS cells
The full details of each mutation are in Supplementary Table 1.
Cell Line Mutated Genes
Number of
Non-Silent
Mutations
Detectable at Low
Frequency in
Fibroblasts?
CF-RiPS1.4 OR52E8, TEAD4 1 N/A
CF-RiPS1.9
OR52E8, FAM171A1, TMED9,
TEAD4, RASEF 3 N/A
CV-hiPS-B
MMP26, DYNC1H1, VMO1,
DSC3, CELSR1, FLT4,
UBE2CBP, ARHGEF5,
IGF2BP3, DLG3 7 7/8
CV-hiPS-F
IQGAP3, SPEN, TNR, PBLD,
OR6Q1, INTS4, GSG1, NTRK3,
DNAH3, GOLGA4, FAT2,
C6orf25, UBR5, SDR16C5 12 4/7
DF19.11
SPATA21, RGS8, RP4-
788L13.1, KCNJ8, SETBP1,
ZNF471, TMEM40 5 N/A
DF6-9-9
ZZZ3, AKR1C4, NEK5, DAPL1,
ITCH, PPP1R2 5 0/5
dH1CF16-iPS1 IRGQ, TM9SF4 1 N/A
dH1CF16-iPS4
PKP1, MYOG, ABCA3, PTPRM,
RANBP3L, CALN1 4 N/A
dH1F-iPS8
CABC1, C1orf100, OR5AN1,
CACNG3, MYRIP, SLC1A3,
DSP, KLRG2 6 N/A
dH1F-iPS9 SEMA6C, MYRIP, SLC1A3 3 N/A
FiPS3F1
SORCS3, GLRA3, CARM1,
EPB41L1 2 N/A
FiPS4F7 GDF3, ZER1 2 N/A
iPS11A
GTF3C1, SAL1, SLC26A3,
ZNF16 3 1/1
iPS11B
MARCKSL1, PRDM16, ATM,
LRP4, TCF12, SH3PX3,
OSBPL3 5 0/1
iPS17A
HK1, ANKRD12, SCN1A,
IFNGR1 4 N/A
iPS17B
HK1, CCKBR, ANKRD12,
SCN1A, IFT122 5 1/1
iPS29A PRICKLE1, RFX6 2 2/2
iPS29E
C14orf174, NTRK3, VAC14,
ASB3, STX7, POLR1C, LINGO2 6 1/4
iPS4.7
POLE, UBA2, L3MBTL2,
C4orf41 2 N/A
PGP1-iPS C11orf67, OSBPL8, NEK11 1 1/3
FiPS4F2
TMEM57, RANBP6, CTSL1,
SAV1, KRT25, BCL2L12,
LGALS1, TTYH2*, COPA*,
ARSB*, MT1B* 7 N/A
FiPS4F-shpRB4.5
NTRK1, CD1B, LRCH3,
SH3TC1, GPC2, CDK5RAP2,
MYH4, TRMU 5 N/A
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*
Mutation was observed at passage 40 but not at passage 9. FiPS4F2 was sequenced at both passage 9 and passage 40. Six mutations were present 
after reprogramming (FiPS4F2P9), while four more became fixed after extended culture (FiPS4F2P40). All six mutations found after 
reprogramming were also present after extended culture.
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